Generics 21

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Dimethyl fumarate manufacturers

21 products found

Filters

21 products found

dimethyl fumarate

Capsules, gastro resistant (GR) 120 mg, 240 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Available for
Licensing with supply
Manufacturer #16163
As a result of a strategic agreement with a company delivering an attractive high-quality portfolio with European supply, it is a trustworthy B2B partner with more than 30 years of experience in the out-licensing business model. The organization is a reliable commercial partner that takes a customer-centric approach and strives for long-term partnership development to secure market success.

Manufacturer usually replies in 8 days

dimethyl fumarate

Capsules 120 mg, 240 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Ref: Tecfidera®
Manufacturer #252

Manufacturer usually replies in 4 days

dimethyl fumarate

Oral suspension 120 mg/2 ml

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Modified release oral suspension. Early stage
Manufacturer #8593
It is a private R&D and business development organization established in the 2000s, specializing in the design and development of new pharmaceutical products worldwide. They have an average of 5-6 new developments per year, an average of 8-10 DCPs per year, more than 60 dossier updates in the last 10 years, they have more than 3 valid and approved patent applications, and approximately 140 MAs worldwide.

Manufacturer usually replies in 2 days

Want to see all 21 products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Dimethyl fumarate

Dimethyl fumarate is the fumaric acid of the methyl ester. It is named after the earth smoke plant called Fumaria officinalis. Dimethyl fumarate treats various forms of multiple sclerosis, a disease in which the nerves do not function properly and people may experience weakness, numbness, loss of muscle coordination, and problems with vision, speech, and bladder control) among adults. These include clinically isolated syndrome, its nerve symptom episodes that last at least 24 hours, for relapsing-remitting forms or secondary progressive forms. Dimethyl fumarate is an Nrf2 activator, whose actions decrease inflammation and prevent nerve damage caused by multiple sclerosis. It has great immunomodulatory properties while not suppressing the immune in adults. DMF is sold for psoriasis treatment and sold as an oral formulation mixed with related compounds in Germany. In the UK, it is sold as a pure oral formulation. It is sold in the U.S. as an oral formulation to treat adults with relapsing multiple sclerosis. Dimethyl fumarate is sold under the brand name Skilarence & Tecfidera, just to name a few. Walter Schweckendiek, a German chemist first used fumaric acid, as a topical formulation for psoriasis in 1959. Fumapharm, The Swiss company, brought Fumaderm, an oral formulation of Dimethyl fumarate in Germany in 1994 to treat psoriasis.

Dosage and administration

Dimethyl fumarate is sold as 30 mg and 120 mg tablets. In the treatment of multiple sclerosis, the standard adult doses are 120 mg and 240 mg, with the maximum daily dose limited to 480 mg. The user is given a starting dose of 120 mg twice a day, orally. After a week, they are given a maintenance dose of 240 mg twice a day, orally. Reductions in dose are considered for individuals who do not tolerate the maintenance dose, however, the dosage should resume within 4 weeks. If users are unable to tolerate a return to the maintenance, the treatment is discontinued.

The cost of Dimethyl fumarate

In the UK, the annual cost of treatment on Dimethyl fumarate is £17,900 year. In the USA, the consumer has to pay an average retail price of $11,646.72 for a course of annual treatment.

How does Dimethyl fumarate work?

Dimethyl fumarate's main action is immunomodulation. This results in shifting T helper cells from the Th1 and Th17 profile to a Th2 phenotype. Dimethyl fumarates reduce the production of Inflammatory cytokines by inducting proapoptotic events. It also inhibits keratinocyte proliferation, reduces the expression of adhesion molecules in addition to diminishing the inflammatory infiltrate within psoriatic plaques. It is also shown to reduce the expression of micro-RNA-2. This is essential for producing pathogenic cells in multiple sclerosis and psoriasis. DMF achieves this through cell-permeable metabolites that epigenetically regulate the expression of micro-RNA-21, which it does through metabolic- epigenetic interplay during the development of immune cells in the body.

Finding DMF Manufacturers and Suppliers:

The process of finding trusted DMF manufacturers and DMF suppliers can be made quicker and more accessible by using Pipelinepharma's online platform, a B2B marketplace that lets you finalize the deals of pharmaceutical products in a matter of a few clicks. Also, it is an easy to use an online platform to grow your business opportunities. The robust search engine makes it convenient to search for manufacturers and suppliers of DMF. The search can be further refined with industry-specific filters such as dossier type, country of origin, GMP approvals, and search criteria for Wholesaler, etc. helping to get in contact with the preferred manufacturer and supplier readily.

Interested in becoming a subscriber?

Please provide the following information to receive an offer tailored to your business needs

  1. Number of company users for the subscription
  2. The rough number of products you would like to source in the 12 months
  3. Target market(s) for commercialisation